A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,829
- 试验地点
- 1
- 主要终点
- Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion Revascularization
研究概览
简要总结
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial. Interventional procedures will be performed to reflect current and evolving standards, including predominant radial access. All patients will be treated with routine oral anti-platelet therapy pre-procedure. GP IIb/IIIa inhibitors will be reserved for 'bail out' treatment only.
详细描述
HEAT-PPCI is a single-centre prospective, dual-arm, open-label, randomised controlled trial comparing two antithrombotic agents in patients undergoing PPCI. All patients presenting to the PPCI service at Liverpool Heart and Chest Hospital will be assessed for trial eligibility. The patients will be allocated by randomisation in equal proportions to the two treatment groups receiving UFH (70 units/kg prior to the procedure) or bivalirudin (bolus of 0.75 mg/kg prior to the start of the intervention, followed by an infusion of 1.75 mg/kg per hour for the duration of the procedure).
Pre-Specified Subgroup Analyses
- Subgroup analyses looking at the impact of access site comparing radial versus femoral route
- Assessment of the outcomes in diabetic patients receiving oral hypoglycaemic or insulin therapy versus all other patients
- Comparing the outcomes in patients < or ≥ 75 years of age
- Type of p2y12 receptor inhibiting antiplatelet agent (Examples: clopidogrel, prasugrel, ticagrelor)
- Patients with impaired LV function versus normal LV function
- Patients managed with actual or attempted primary PCI versus no immediate PCI procedure attempted
PLATELET FUNCTION SUBSTUDY A substudy will be performed to assess indices of coagulation and platelet function studies comparing the impact of heparin or bivalirudin therapy on coagulation status at the end of the PPCI procedure. This study will be performed on all patients treated between the hours of 0800 and 1600, Monday to Friday. A single blood sample taken at the time of general blood sampling for routine clinical screening will be analysed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients presenting with a suspected myocardial infarction event with PPCI as the proposed index reperfusion strategy will be included in the trial
排除标准
- •≤ 18 years of age
- •Known intolerance, hypersensitivity or contraindication to any trial medication
- •Active bleeding at presentation
- •Artificial ventilation, reduced conscious level or other factors precluding the administration of oral antiplatelet therapy
- •Previous enrolment in this trial
研究组 & 干预措施
Unfractionated heparin
70 units/kg body weight intravenous
干预措施: unfractionated heparin (Drug)
bivalirudin
intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
干预措施: Bivalirudin (Drug)
结局指标
主要结局
Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion Revascularization
时间窗: 28 days
Type 3-5 Bleeding According to BARC (Bleeding Academic Research Consortium)Definition
时间窗: 28 days
次要结局
- All Cause Mortality(1 year)
- CKMB Release Following Index Revascularisation Measured With a Single Estimation 12-18 Hours After the Procedure(28 days)
- Minor Bleeding: Type 2 Bleeding According to BARC (Bleeding Academic Research Consortium) Definition(28 days)
- Stent Thrombosis Rate (ARC Definite or Probable)(28 days)
- For Illustration, and to Allow Comparison With Existing Trials the Rate of Net Adverse Clinical Events (NACE), Combining the Primary Safety and Efficacy Outcomes(28 days)
- Development of Thrombocytopenia(28 days)
- Door-to-first Device Time(28 days)
研究者
Dr Rod Stables
Consultant Cardiologist
Liverpool Heart and Chest Hospital NHS Foundation Trust